Fig. 7: T9 CAR-T cells exert greater antitumor activity in solid tumor models.
a NSG mice were inoculated with 2 × 106 of NALM6 cells subcutaneously. After 14 days, mice were randomly assigned to three groups and infused intravenously with 30 × 106 CAR-T cells. b Tumor volume in mice treated with T1 or T9 CAR-T cells. c Kaplan–Meyer survival plots for CAR-T cell-treated mice (n = 5 mice). Exact P values from log-rank test are shown for T1 versus T9 CAR-T cell-treated mice. d Representative flow plots showing frequency of CAR-T cells in peripheral blood of treated mice at indicated days after CAR-T infusion. e Percentage of CAR-T cells in peripheral blood of treated mice measured at days 8 and 12 after CAR-T cell infusion (n = 5 mice). f Representative flow plots showing the frequency of tumor-infiltrating CAR-T cells at day 12 after CAR-T cell infusion. g Percentage of tumor-infiltrating CAR-T cells at day 12 after CAR-T cell infusion (n = 5 mice). h NSG mice were inoculated with 3 × 106 of HepG2 cells subcutaneously. After 14 days, mice were randomly assigned to three groups and infused intravenously with 10 × 106 CAR-T cells. i Representative tumor images from mice treated with the indicated T cells or PBS on day 24. j Growth curve of HepG2 xenografted mice treated with the indicated T cells or PBS (n = 5 mice). k Flow plots (left panels) and l summarized data (right panels; n = 4 mice) showing frequency of CAR-T cells in peripheral blood of treated mice at indicated days after CAR-T infusion. m, n Percentage of tumor-infiltrating CAR-T cells at day 12 after CAR-T cell infusion (n = 5 mice). Data are presented as mean ± SD. *P < 0.05 and ***P < 0.001, two-sided Student’s t-test. Source data are provided as a Source Data file.
